Clinical effect of recombinant human erythropoietin on patients with primary brain stem injury
10.3760/cma.j.issn.1008-6315.2015.04.002
- VernacularTitle:重组人促红细胞生成素治疗原发性脑干损伤32例效果分析
- Author:
Yilei XIAO
;
Jie ZHOU
;
Zhongmin LI
;
Jianxin ZHU
;
Zonglei ZHONG
;
Chuanjun GUO
;
Fengyang GENG
;
Weijie ZHU
- Publication Type:Journal Article
- Keywords:
Recombinant human erythropoietin;
Primary brain stem injury;
Neurological function
- From:
Clinical Medicine of China
2015;(4):292-294,295
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the short-term curative effect and safety of recombinant human erythropoietin(rHu-EPO)on patients with primary brain stem injury. Methods Sixty patients with primary brain stem injury were recruited at Liaocheng People' Hospital from July 2010 to July 2013. All cases were randomly divided into EPO group and control group. The patients in EPO group were injected subcutaneous with rHu-EPO five times at dose of 6 000 U,while patients in the control group were treated with placebo in 2 weeks. All other conventional treatments were the same. NIHSS score and GOS score were evaluated in two weeks and three months respectively. Moreover,blood pressure and hemoglobin were also measured. Results NIHSS score in EPO group was 11. 37 ± 7. 78,significant higher than that of control group after two weeks(19. 41 ± 8. 26,P = 0. 019). GOS score in EPO group was also significant differences in two groups after three months (Z = - 2. 367,P = 0. 009 ). However,no significant difference was observed in the followed-up blood tests. Conclusion Recombinant human erythropoietin could be the exact nerve protective effect,and might be an effective therapy for patients with primary brain stem injury.
